Topic Archives: ovarian cancer

Everyone seems to love a “micro cap” these days, so the latest teaser pitch from Dylan Jovine over at Behind the Markets for his “upgrade” newsletter caught my eye — it’s called Breakthrough Wealth ($997/yr, 30-day refund policy), and he’s pitching a service that he says will be shooting for 1,000% gains in small companies. […]

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

Comments

  • I got the privilege of watching ovarian cancer take the life of my older sister. She didn't smoke, watched what she ate,...

  • In 1975 Dr Richardson treated my mother, who had stage 4 ovarian cancer. The Laetrile made her vomit blood and rapid...

  • Be clear on this: NK cells are part of the INNATE immune system. But unless they work 100 percent and fully, tumors rela...

  • $Ovarian Cancer. Wow, early detections would be a godsend for all cancers, especially Ovarian cancer (OC). Terrible di...

  • $VBLT VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cance...

  • $FATE long - Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Can...

  • I have a friend who rejected chemo/traditional treatment and went on Dr. Gonzalez's regimen some 20 years ago for her ov...

  • NP $ VBLT 07:01 VBLT Vascular Biogenics announces that the EMA has designated ofranergene obadenovec (VB-11...

  • $FATE long - Fate Therapeutics Reports Second Quarter 2017 Financial Results http://ir.fatetherapeutics.com/releasede...

  • $VBLT ow position VBLT had its quarterly conference call today. Here are some highlights. The only thing I found ...

  • Good Dr. Interesting that you cite IPIX's (formerly CTIX) Kevetrin, which the FDA gave Orphan Drug designation to IPI...

  • My mom was a almost a 20.year ovarian cancer survivor..She was the bad ass in family. Always with grace. She outlive my ...

  • Hi Ron: Thanks for posting this. I had a look at Oncolix, whose lead agent is a single amino acid substituted protein th...

  • About $AEPP sp, Oncolix, and $ARTH fp Many thanks, Doc, for your new column….since reading it last evening ...

  • I need to take my daughter to the dentist, but wanted to throw this out there--yesterday (or this morning?) $VBLT releas...

  • $VBLT np – The data looks good. Dr. KSS when you get time, would love to hear your take on it. For both rGBM and Ovari...

  • $CLVS $TSRO #PARP Hi Doc, I beg to differ - just slightly - with regard to your statement that "The agent (Clovis' ru...

  • $CLVS became the hottest takeout target in oncology this morning by announcing phase 3 data for PARPi rucaparib. The age...

  • $BIOC I think it's completely justified to be disappointed at the slow uptake since last years big jump. So far, it ap...

  • $TSRO - former long. *DJ TESARO Announces Availability of Zejula (Niraparib) for Patients With Recurrent Ovarian Cancer ...

  • RVW: be careful. First $TLOG may be planning to reverse merge....I'm not sure. Second, I have concerns this is not exact...

  • $CTIX SMALL LONG BEVERLY, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (the Compan...

  • TESARO (TSRO) Announces FDA Approval of its PARP Inhibitor, ZEJULA, for Treatment of Women With Recurrent Ovarian Cancer...

  • $TSRO TESARO Announces U.S. FDA Approval Of ZEJULA(TM) (Niraparib) For Women With Recurrent Ovarian Cancer TESARO A...

  • $TSRO $CLVS $AZN SunTrust analyst just issued a research report on the competitive scene of PARP inhibitors: "TESA...

  • $TSRO long It appears, as so often in bio, that this company's SP is reacting to news about a competitor. Astra-Ze...

  • I've done a little research on my own and the company doing the most research and development on gold protocal cancer tr...

  • Thanks for posting. I predict failure for this trial. You'd have to know the pathways and the molecular genetics, but pl...

  • $AZN $JNJ $NVS $PFE $NVO $RHHBY $GSK $TEVA $BIIB $LLY $TSRO $NBIX $KITE $PBYI *The top 15 would-be blockbusters in t...

  • $SNDX Syndax anticipates making a go/no go decision to progress into the second stage for each arm of ENCORE 601 in the...

  • $VBLT: VBL Therapeutics Provides Year End 2016 Corporate Update January 9, 2017 TEL AVIV, Israel, Jan. 09, 2017 (...

  • STM: Please don't rush out to sell your $CLVS yet...the company did win an early approval on December 18, 2016 for its P...

  • re: Holdings. Thanks for both the initial suggestions and the offer to provide more granular feedback. I'll be the f...

  • $CLVS np but order in during halt! FDA approves ovarian cancer treatment Rubraca Looking to scalp this today only....

  • $TSRO yes. I admit Tesaro kind of caught me napping. The problem is PARP inhibitors, which Tesaro has. There have been S...

  • As a $TSRO shareholder, I can share some of my experience.On June 30th Tesaro did a similar secondary (pricing and total...

  • J&J talc suit news; Short URL| Email Article| Comment| Contact| Print| A A After a $67.5 million jury verdic...

  • Unfortunately most mistakes are covered up and unreported. I had an older sister that didn't smoke or drink, ate the rig...

  • Very dazzling performance especially in ovarian cancer, with nearly half of all patients responding in some fashion. Ver...

  • $GILD $TSRO: I'd like to offer an alternative view: when and if Gilead makes a major move in acquisition, its growth...

  • Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research P...

  • This is in response to linling, who wrote last night asking about PARP inhibitors and the companies advancing them, such...

  • $BIOC no position. A company listed in London, ANGLE plc (AGL) and on OTC-QX (ANPCY), claims its ParsortixTM microfluidi...

  • Very nice and useful article Doc, thanks so much. As far as what a SPA means here is a link that explains thoroughly wha...

  • It is with profound interest to learn about this new Magic $1 Pill, so much so, I decided to subscribe to become a membe...

  • Recent advances in treating Ovarian Cancer. http://blog.aacr.org/recent-advances-treating-ovarian-cancer/ Cheers,G...

  • I joined a trading app called Robinhood.com. I put $2000 in there. Had to wait 3 days for it to become active. Today I b...

  • I must admit I am disappointed at the relative lack of compellingness of the literature I have found on the talc/ovary c...

  • Epidemiology of talc and ovarian cancer http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820665/ http://www.ncbi.nlm.nih.g...

  • Doc, please let us know about the studies that do link talc with ovarian cancer, as what I am seeing does not point that...

  • Sharon: I say this just trying to have your back covered because I care about what happens to your investments: I agree ...

  • Seems safest bet is don't dust the rug. My mother died of ovarian cancer and i remember her being in clouds of talcum c...

  • JNJ: The International Agency for Research on Cancer (IARC) is part of the World Health Organization (WHO). Its major go...

  • Johnson and Johnson: Second woman awarded $86mil as baby powder can cause ovarian cancer. Anyone who is still long sho...

  • My mom had ovarian cancer in the early 90's. They did a hysterectomy.. then radiation.. She made it 18 years after..(whi...

  • interesting Stem Cell studies released today in Prostate and Ovarian Cancer. http://journals.lww.com/oncology-times/blo...

  • I am a medical practitioner. I look at this drug from a different perspective than I have been reading out there in 'te...

  • $CTIX Cellceutix meets fda phase-2 clinical trial kevetrin ovarian cancer http://seekingalpha.com/pr/16152296-cellceut...

  • For those still in $CTIX,: Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer...

  • Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer BEVERLY, MA--(Marketw...

  • Ovarian cancer drug shows promise with prostate cancer. http://www.ptcommunity.com/news/2015-10-29-000000/ovarian-can...

  • $CTIX: Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines ...

  • This New York Times article is important reading, particularly if you know someone with ovarian cancer. A treatment w...

  • A fascinating report out of MD Anderson this morning: among women with ovarian cancer who take beta-blockers for any ind...

  • Peering in at mid-day to answer Glenn's question about Oxigene, a $36M South San Francisco company that has stayed liste...

  • Doc Kss,when you get a chance could I get your thoughts on this company Oxigene(OXGN) and their drug ZYBRESTAT working w...

  • This company looks interesting Vermillion (VRML) with their OVA1 diagnostic blood test for pre-surgical assessment of ov...

  • Obviously if you're in $CTIX here, hold. But the casus diabli is this. Kevetrin is YEARS away from being proven to have ...

  • $CTIX Kevetrin granted Orphan Drug Designation for Ovarian Cancer yesterday. Here is the link: http://www.accessdata....

  • Yes, but for ovarian cancer, not breast...orphan drug designation made 7-14-15. Can't easily post a link right now but ...

  • Hi Sharon: Yes, while cancers do have elaborate immune-deterrent mechanisms, as long as they have an exposed surface mem...

  • Good article. (The Scientist becomes the Survivor and Advocate) fighting ovarian cancer. http://blog.aacr.org/laura-sha...

  • I've been flat on my back for the last three days with the Cold from Hell. so if I reiterate other posting I apologize i...

  • Hi Dr. KSS I mentioned 2 days ago about PBMD and that it was up 200% from .50 cents. Now today it is at $5.65. th...

  • Wow! Thanks for the input, Pat -- I bought a few shares of PBMD to make it correct downward. Positive phase II ovarian...

  • PBMD / just noticed the huge jump on this stock today, up over 200%. I am not a bio mind does anyone know anythin...

  • $KPTI. from leerink asco abstracts. • KPTI (OP): Ph II data for selinexor suggests single agent activity in solid...

  • Doc KSS, this company Novogen (NVGN) appear to have some very nice pre-clinical work in oncology and were once merged wi...

  • $CTIX-e-mail Best2ALL!-Benjamin My Fellow Cellceutix Shareholders, We are pleased to inform you that Cellceutix Chie...

  • One promising area is turning on the body's own defense against cancer -- the p53 "guardian angel" gene. CTIX announced ...

  • Diana, about $CTIX and your excellent comments above: (1) Personally I find Alexander's reassurances about the non-to...

  • Dr. thank you for the great continuing education about how to evaluate trial news and hypes! I listened again to the 201...

  • I am putting $CTIX on notice: THIS kind of press release has no place, and if this sort of thing continues I am exiting....

  • Cellceutix Reports Spleen Lesion 'Disappears' in Patient With Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Ant...

  • Northwest Biotherapeutic (NWBO) might deserve a mention in this list. NW Bio is Developing dendritic cell-based vaccines...

  • Scorpio, here is a link that works now: http://edge.media-server.com/m/p/ya62u49c Some new details fleshed out a little...

  • Certain traders who need to lighten up on the benzedrine. People read a press release and seem to have flipped because t...

  • It's a psychotic overreaction to news that is not bad. (1) the ovarian cancer is the least interesting of all TLOG stud...

  • TLOG-TetraLogic Provides Update on Ovarian Cancer Study 7:00a ET December 16, 2014 (GlobeNewswire) TetraLogic Pharmaceu...

  • Mary was asking about Clovis $CLVS. I can't say I have found anything negative to explain the recent down move. I think ...

  • $CLVS update on ovarian cancer trial Clovis Oncology, Inc. has added a news release to its Investor Relations web...

  • Interesting bullish article today on SA regarding $CLVS by an author who I follow. One of the key theses is that a ovar...

  • Will respond to more comments this evening, but one other thing in brief: Oxigene ($OXGN) recently presented data on its...

  • Thomas: (1) keep in mind that phase 1 will have no data til fall 2016...2 years away! Unless it proves highly toxic. ...

  • In my view, Atara is overpriced here. It appears to have only one agent in a phase 1 trial, one being studied in ovarian...

  • Glenn asked last night about $PBMD Prima BioMed, an early stage Australian company that has just purchased Paris immunol...

  • Dr.KSS: Any thoughts on a new IPO called Atara Biotechnology $ATRA? Impressive management. Partnership with MSKCC in dev...

  • I wonder if those same families who are insisting that everything possible be done, would do so if at least some of the ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info